These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15848615)

  • 1. Cyclosporine and tacrolimus: influence on cardiovascular risk factors.
    Hohage H; Hillebrandt U; Welling U; Zeh M; Heck M; Gerhardt UW; Suwelack BM
    Transplant Proc; 2005 Mar; 37(2):1036-8. PubMed ID: 15848615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study.
    Hohage H; Welling U; Zeh M; Gerhardt U; Suwelack B
    Transplant Proc; 2005 May; 37(4):1898-9. PubMed ID: 15919497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
    Hohage H; Welling U; Heck M; Zeh M; Gerhardt U; Suwelack BM
    Int Immunopharmacol; 2005 Jan; 5(1):117-23. PubMed ID: 15589469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
    Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
    Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2007 Dec; 39(10):3135-41. PubMed ID: 18089339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
    Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
    Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients.
    Hohage H; Arlt M; Brückner D; Dietl KH; Zidek W; Spieker C
    Clin Transplant; 1997 Jun; 11(3):225-30. PubMed ID: 9193847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M; Morales JM; Marcen R; Campistol JM; Oppenheimer F; Serón D; Gil-Vernet S; Capdevila L; Andrés A; Lampreave I; Del Castillo D; Cabello M; Burgos D; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
    Transplant Proc; 2007 Sep; 39(7):2167-9. PubMed ID: 17889126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
    Neal DA; Gimson AE; Gibbs P; Alexander GJ
    Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients.
    Kanbay M; Akcay A; Huddam B; Usluogullari CA; Arat Z; Ozdemir FN; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3119-20. PubMed ID: 16213325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II.
    Marcard T; Ivens K; Grabensee B; Willers R; Helmchen U; Rump LC; Blume C
    Transpl Int; 2008 Dec; 21(12):1153-62. PubMed ID: 18684111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
    Beckebaum S; Klein C; Varghese J; Sotiropoulos GC; Saner F; Schmitz K; Gerken G; Paul A; Cicinnati VR
    Aliment Pharmacol Ther; 2009 Oct; 30(8):834-42. PubMed ID: 19624550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and risk factors of renal dysfunction after liver transplant: a single-center experience.
    Dehghani SM; Derakhshan A; Taghavi SA; Gholami S; Jalaeian H; Malek-Hosseini SA
    Exp Clin Transplant; 2008 Mar; 6(1):25-9. PubMed ID: 18405241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
    Gelens MA; Christiaans MH; v Hooff JP
    Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk estimates and risk factors in renal transplant recipients.
    Krämer BK; Böger C; Krüger B; Marienhagen J; Pietrzyk M; Obed A; Paczek L; Mack M; Banas B
    Transplant Proc; 2005 May; 37(4):1868-70. PubMed ID: 15919488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity?
    Martins L; Ventura A; Branco A; Carvalho MJ; Henriques AC; Dias L; Sarmento AM; Amil M
    Transplant Proc; 2004 May; 36(4):877-9. PubMed ID: 15194300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.